By Mike Ward
Editor, Europe

OXFORD - European regulatory authorities are taking some first steps to increase the transparency of the process for drug approvals. But the process remains - and appears likely to remain - far more secretive than the comparable regulatory situation in the U.S. despite the call of some European campaigners for a more transparent and rigorous European drug approval system.